Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Monday, October 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alliance Foundation Trials and Natera have launched the AFT-70 NAVIGATE trial, a randomized phase III study. This trial aims to evaluate a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The collaboration seeks to enhance treatment efficacy and patient outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of a novel MRD-guided treatment strategy
  • Collaboration between AFT and Natera enhances clinical trials
  • Focus on improving outcomes for breast cancer patients

Full Press Release Details

BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cance

Frequently Asked Questions

What is the AFT-70 NAVIGATE trial?

The AFT-70 NAVIGATE trial is a randomized phase III study evaluating MRD-guided treatment for breast cancer.

Who are the collaborators for the AFT-70 NAVIGATE trial?

The trial is a collaboration between Alliance Foundation Trials and Natera.

What type of breast cancer does the trial focus on?

The trial focuses on intermediate and high-risk ER-positive/HER2-negative early breast cancer.

What is the goal of the AFT-70 NAVIGATE trial?

The goal is to evaluate a novel MRD-guided treatment strategy to improve patient outcomes.

ShareAdd on Google
Tags: NTRA Natera AFT-70 NAVIGATE breast cancer clinical trials MRD-guided therapy
Last updated: Oct 5, 2026

Biotech snapshot

Cash runway
$1092M liquidity · $0M/mo burn
Low dilution risk